1
项与 CD19/CD22/BCMA CAR-T(Shanghai Cell Therapy Group) 相关的临床试验A Dose Escalating Study of CD19/CD22/BCMA Three Targets Autologous Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous chimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA in patients with relapsed or refractory B cell non-Hodgkin lymphoma.
100 项与 CD19/CD22/BCMA CAR-T(Shanghai Cell Therapy Group) 相关的临床结果
100 项与 CD19/CD22/BCMA CAR-T(Shanghai Cell Therapy Group) 相关的转化医学
100 项与 CD19/CD22/BCMA CAR-T(Shanghai Cell Therapy Group) 相关的专利(医药)
100 项与 CD19/CD22/BCMA CAR-T(Shanghai Cell Therapy Group) 相关的药物交易